t
On 22 June 2026, Proteome Sciences plc announced it secured a further significant clinical contract. This contract is connected to the company's target engagement/chemoproteomics platform.
| Date | 22 Jun 2026 |
| Time | 07:00:08 |
| Category | Corporate updates |
| ID | 1061J |
22 June 2026
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation
("Proteome Sciences" or the "Company")
Target engagement/chemoproteomics contract
Proteome Sciences plc (AIM:PRM) is pleased to announce that the Company has secured a further significant clinical contract connected to its target engagement/chemoproteomics platform. The Company anticipates this contract being a precursor to a new clinical trial programme that will be initiated later in 2026.
Christopher Pearce, Executive Chairman, commented:
"We are delighted that the momentum and growth from our chemoproteomics services is continuing in the current year, as highlighted by this new contract. The Company also generated considerable interest and attention at the recent American Society for Mass Spectrometry (ASMS) meeting in San Diego, USA earlier in June and we look forward to providing shareholders with further updates regarding our chemoproteomics workstreams in due course".
|
Proteome Sciences plc |
|
|||
|
Christopher Pearce, Executive Chairman |
Tel: +44 (0) 20 7043 2116 |
|
||
|
Richard Dennis, Chief Commercial Officer |
|
|
||
|
SP Angel Corporate Finance LLP (Nominated Adviser & Broker) |
|
|
||
|
David Hignell/Matthew Johnson/Josh Ray (Corporate Finance) Vadim Alexandre (Corporate Broking) |
Tel: +44 (0) 20 3470 0470 |
|
||
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, with analysis using a range of depletion strategies in combination with TMTcalibrator™ providing access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Chemoproteomics using Solvent Shift reveals the selectivity that drugs have to binding one or more proteins in the sample proteome. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
Further information on the Company can be found on its website at: https://www.proteomics.com/
The Company's LEI is 213800Q62ICXANKU2986.